Cargando…
Cost‐of‐illness study for axillary hyperhidrosis in Japan
The prevalence of primary axillary hyperhidrosis in Japan is 5.75% (males, 6.60%; females, 4.72%) in the population aged 5–64 years. No study on comprehensively evaluated direct medical costs, hygiene product costs, and productivity loss in axillary hyperhidrosis patients has been published in Japan...
Autores principales: | Murota, Hiroyuki, Fujimoto, Tomoko, Oshima, Yuichiro, Tamada, Yasuhiko, Yanagishita, Takeshi, Murayama, Naoya, Inoue, Sachie, Okatsu, Hiromichi, Miyama, Hiroshi, Yokozeki, Hiroo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518070/ https://www.ncbi.nlm.nih.gov/pubmed/34245048 http://dx.doi.org/10.1111/1346-8138.16050 |
Ejemplares similares
-
Two‐week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis
por: Fujimoto, Tomoko, et al.
Publicado: (2022) -
Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double‐blind, vehicle‐controlled study
por: Yokozeki, Hiroo, et al.
Publicado: (2021) -
Questionnaire-based epidemiological survey of primary focal hyperhidrosis and survey on current medical management of primary axillary hyperhidrosis in Japan
por: Fujimoto, Tomoko, et al.
Publicado: (2022) -
Effects of Direct Current Administration on Hyperhidrosis Disease Severity Scale in Patients with Axillary Hyperhidrosis
por: Şener, Serpil, et al.
Publicado: (2019) -
A phase III, 52‐week, open‐label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis
por: Fujimoto, Tomoko, et al.
Publicado: (2021)